Myocardial ATGL overexpression decreases the reliance on fatty acid oxidation and protects against pressure overload-induced cardiac dysfunction

Molecular and Cellular Biology

Volumn 32, Issue 4, 2012, Pages 740-750

  Kienesberger, Petra C ^a   Pulinilkunnil, Thomas ^a   Sung, Miranda M Y ^a   Nagendran, Jeevan ^a   Haemmerle, Guenter ^b   Kershaw, Erin E ^c   Young, Martin E ^d   Light, Peter E ^e   Oudit, Gavin Y ^a   Zechner, Rudolf ^b   Dyck, Jason R B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOSE TRIGLYCERIDE LIPASE; CERAMIDE; DIACYLGLYCEROL; LONG CHAIN ACYL COENZYME A DEHYDROGENASE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENERGY METABOLISM; FATTY ACID OXIDATION; GENE OVEREXPRESSION; GLUCOSE OXIDATION; HEART DISEASE; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE; HEART MUSCLE CELL; HYDROLYSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BASE SEQUENCE; DNA PRIMERS; ENERGY METABOLISM; FATTY ACIDS; GLUCOSE; HEART DISEASES; LIPASE; MALE; MICE; MICE, TRANSGENIC; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOCYTES, CARDIAC; OXIDATION-REDUCTION; RECOMBINANT PROTEINS; TRIGLYCERIDES; UP-REGULATION;

EID: 84856807853     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.06470-11     Document Type: Article

References (48)

1. Ahmadian M, et al. 2009. Adipose overexpression of desnutrin promotes fatty acid use and attenuates diet-induced obesity. Diabetes 58:855-866.
2. Banke NH, et al. 2010. Preferential oxidation of triacylglyceride-derived fatty acids in heart is augmented by the nuclear receptor PPARalpha. Circ. Res. 107:233-241.
3. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP. 2000. Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J. Clin. Invest. 105:1723-1730.
4. Birse RT, et al. 2010. High-fat-diet-induced obesity and heart dysfunction are regulated by the TOR pathway in Drosophila. Cell Metab. 12:533-544.
5. Borradaile NM, Schaffer JE. 2005. Lipotoxicity in the heart. Curr. Hypertens. Rep. 7:412-417.
6. Caviglia JM, De Gomez Dumm IN, Coleman RA, Igal RA. 2004. Phosphatidylcholine deficiency upregulates enzymes of triacylglycerol metabolism in CHO cells. J. Lipid Res. 45:1500-1509.
7. Chiu HC, et al. 2001. A novel mouse model of lipotoxic cardiomyopathy. J. Clin. Invest. 107:813-822.
8. Christoffersen C, et al. 2003. Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. Endocrinology 144:3483-3490.
9. Folch J, Lees M, Sloane Stanley GH. 1957. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226:497-509.
10. Fullerton MD, Hakimuddin F, Bonen A, Bakovic M. 2009. The development of a metabolic disease phenotype in CTP:phosphoethanolamine cytidylyltransferase-deficient mice. J. Biol. Chem. 284:25704-25713.
11. Gao S, et al. 2007. Leptin activates hypothalamic acetyl-CoA carboxylase to inhibit food intake. Proc. Natl. Acad. Sci. U. S. A. 104:17358-17363.
12. Glenn DJ, et al. 2011. A murine model of isolated cardiac steatosis leads to cardiomyopathy. Hypertension 57:216-222.
13. Gulick J, Subramaniam A, Neumann J, Robbins J. 1991. Isolation and characterization of the mouse cardiac myosin heavy chain genes. J. Biol. Chem. 266:9180-9185.
14. Guo D, et al. 2010. Loss of PI3Kgamma enhances cAMP-dependent MMP remodeling of the myocardial N-cadherin adhesion complexes and extracellular matrix in response to early biomechanical stress. Circ. Res. 107:1275-1289.
15. Haemmerle G, et al. 2006. Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science 312:734-737.
16. Haemmerle G, et al. 2011. ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-alpha and PGC-1. Nat. Med. 17: 1076-1085.
17. Heather LC, et al. 2006. Fatty acid transporter levels and palmitate oxidation rate correlate with ejection fraction in the infarcted rat heart. Cardiovasc. Res. 72:430-437.
18. Hirano K, Ikeda Y, Zaima N, Sakata Y, Matsumiya G. 2008. Triglyceride deposit cardiomyovasculopathy. N. Engl. J. Med. 359:2396-2398.
19. Imahashi K, Mraiche F, Steenbergen C, Murphy E, Fliegel L. 2007. Overexpression of the Na+/H+ exchanger and ischemia-reperfusion injury in the myocardium. Am. J. Physiol. Heart Circ. Physiol. 292:H2237-H2247.
20. Jeppesen J, et al. 2011. Contraction-induced skeletal muscle FAT/CD36 trafficking and FA uptake isAMPKindependent. J. Lipid Res. 52:699-711.
21. Kassiri Z, et al. 2005. Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice. Circ. Res. 97:380-390.
22. Khan RS, Drosatos K, Goldberg IJ. 2010. Creating and curing fatty hearts. Curr. Opin. Clin. Nutr. Metab. Care. 13:145-149.
23. Kuang M, Febbraio M, Wagg C, Lopaschuk GD, Dyck JR. 2004. Fatty acid translocase/CD36 deficiency does not energetically or functionally compromise hearts before or after ischemia. Circulation 109:1550-1557.
24. Lee Y, et al. 2004. Hyperleptinemia prevents lipotoxic cardiomyopathy in acyl CoA synthase transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 101: 13624-13629.
25. Leonardi R, Frank MW, Jackson PD, Rock CO, Jackowski S. 2009. Elimination of the CDP-ethanolamine pathway disrupts hepatic lipid homeostasis. J. Biol. Chem. 284:27077-27089.
26. Lerch R, Tamm C, Papageorgiou I, Benzi RH. 1992. Myocardial fatty acid oxidation during ischemia and reperfusion. Mol. Cell. Biochem. 116: 103-109.
27. Lim HY, Wang W, Wessells RJ, Ocorr K, Bodmer R. 2011. Phospholipid homeostasis regulates lipid metabolism and cardiac function through SREBP signaling in Drosophila. Genes Dev. 25:189-200.
28. Liu L, et al. 2009. DGAT1 expression increases heart triglyceride content but ameliorates lipotoxicity. J. Biol. Chem. 284:36312-36323.
29. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. 2010. Myocardial fatty acid metabolism in health and disease. Physiol. Rev. 90: 207-258.
30. Luiken JJ, Willems J, van der Vusse GJ, Glatz JF. 2001. Electrostimulation enhances FAT/CD36-mediated long-chain fatty acid uptake by isolated rat cardiac myocytes. Am. J. Physiol. Endocrinol. Metab. 281:E704-E712.
31. Marfella R, et al. 2009. Myocardial lipid accumulation in patients with pressure-overloaded heart and metabolic syndrome. J. Lipid Res. 50: 2314-2323.
32. McGavock JM, Victor RG, Unger RH, Szczepaniak LS. 2006. Adiposity of the heart, revisited. Ann. Intern. Med. 144:517-524.
33. Ng AC, et al. 2010. Myocardial steatosis and biventricular strain and strain rate imaging in patients with type 2 diabetes mellitus. Circulation 122:2538-2544.
34. O'Donnell JM, Fields AD, Sorokina N, Lewandowski ED. 2008. The absence of endogenous lipid oxidation in early stage heart failure exposes limits in lipid storage and turnover. J. Mol. Cell. Cardiol. 44:315-322.
35. Ong KT, Mashek MT, Bu SY, Greenberg AS, Mashek DG. 2011. Adipose triglyceride lipase is a major hepatic lipase that regulates triacylglycerol turnover and fatty acid signaling and partitioning. Hepatology 53:116-126.
36. Oudit GY, et al. 2008. Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress. Cardiovasc. Res. 78:505-514.
37. Preiss J, et al. 1986. Quantitative measurement of sn-1,2-diacylglycerols present in platelets, hepatocytes, and ras- and sis-transformed normal rat kidney cells. J. Biol. Chem. 261:8597-8600.
38. Reid BN, et al. 2008. Hepatic overexpression of hormone-sensitive lipase and adipose triglyceride lipase promotes fatty acid oxidation, stimulates direct release of free fatty acids, and ameliorates steatosis. J. Biol. Chem. 283:13087-13099.
39. Saddik M, Lopaschuk GD. 1991. Myocardial triglyceride turnover and contribution to energy substrate utilization in isolated working rat hearts. J. Biol. Chem. 266:8162-8170.
40. Schweiger M, Lass A, Zimmermann R, Eichmann TO, Zechner R. 2009. Neutral lipid storage disease: genetic disorders caused by mutations in adipose triglyceride lipase/PNPLA2 or CGI-58/ABHD5. Am. J. Physiol. Endocrinol. Metab. 297:E289-E296.
41. Sentex E, Sergiel JP, Lucien A, and Grynberg A. 1998. Is the cytoprotective effect of trimetazidine associated with lipid metabolism? Am. J. Cardiol. 82:18K-24K.
42. Son NH, et al. 2010. PPARgamma-induced cardiolipotoxicity in mice is ameliorated by PPARalpha deficiency despite increases in fatty acid oxidation. J. Clin. Invest. 120:3443-3454.
43. Tabbi-Anneni I, et al. 2003. Prevention of heart failure in rats by trimetazidine treatment: a consequence of accelerated phospholipid turnover? J. Pharmacol. Exp. Ther. 304:1003-1009.
44. Tappia PS, Singal T. 2008. Phospholipid-mediated signaling and heart disease. Subcell. Biochem. 49:299-324.
45. Tsai JY, et al. 2010. Direct regulation of myocardial triglyceride metabolism by the cardiomyocyte circadian clock. J. Biol. Chem. 285:2918-2929.
46. Turpin SM, et al. 2011. Adipose triacylglycerol lipase is a major regulator of hepatic lipid metabolism but not insulin sensitivity in mice. Diabetologia 54:146-156.
47. Ussher JR, et al. 2009. Insulin-stimulated cardiac glucose oxidation is increased in high-fat-diet-induced obese mice lacking malonyl CoA decarboxylase. Diabetes 58:1766-1775.
48. Zimmermann R, et al. 2004. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science 306:1383-1386.